Integer (ITGR) is facing macroeconomic uncertainty related to tariffs, Oppenheimer said in a note Friday as it lowered its rating on the stock.
"We are adopting a wait and see stance," Oppenheimer said.
The firm said it is "fundamentally constructive" on Integer because of the company's exposure to high-growth MedTech segments.
"Our downgrade is a reflection of the stock being at our price target, and the uncertainty around possible tariff-induced structural dislocations," Oppenheimer said.
Oppenheimer downgraded its rating on Integer stock to perform from outperform, and removed its $138 price target.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。